http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
황순호,임형업,우성주,김신규 慶熙大學校 1994 論文集 Vol.23 No.-
We have synthesized protoberberine derivatives from tetra- hydroberberinium perchlorate. On quaternization of a several protoberberine derivativese with methyl iodide, the formation of the cis methiodides the corresponding trans methiodides increased according to the order of the bulkiness of the 14-substituent as H>CH₃>CN. The N-methyl signal of the cis 14-substituted quinolisidine methiodides was conformed to appear at higher field than those of the corresponding trans methiodides except for the 14-cyano methiodides in their NMR specta.
Minke whale genome and aquatic adaptation in cetaceans
Yim, Hyung-Soon,Cho, Yun Sung,Guang, Xuanmin,Kang, Sung Gyun,Jeong, Jae-Yeon,Cha, Sun-Shin,Oh, Hyun-Myung,Lee, Jae-Hak,Yang, Eun Chan,Kwon, Kae Kyoung,Kim, Yun Jae,Kim, Tae Wan,Kim, Wonduck,Jeon, Jeon Nature Pub. Co 2014 Nature genetics Vol.46 No.1
The shift from terrestrial to aquatic life by whales was a substantial evolutionary event. Here we report the whole-genome sequencing and de novo assembly of the minke whale genome, as well as the whole-genome sequences of three minke whales, a fin whale, a bottlenose dolphin and a finless porpoise. Our comparative genomic analysis identified an expansion in the whale lineage of gene families associated with stress-responsive proteins and anaerobic metabolism, whereas gene families related to body hair and sensory receptors were contracted. Our analysis also identified whale-specific mutations in genes encoding antioxidants and enzymes controlling blood pressure and salt concentration. Overall the whale-genome sequences exhibited distinct features that are associated with the physiological and morphological changes needed for life in an aquatic environment, marked by resistance to physiological stresses caused by a lack of oxygen, increased amounts of reactive oxygen species and high salt levels.
( Tae Hyung Kim ),( Hyung Joon Yim ),( Young-sun Lee ),( Young Kul Jung ),( Han Ah Lee ),( Sun Young Yim ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Soon Ho Um ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: In chronic hepatitis B (CHB), nucleos(t)ide analogues (NAs) cannot exterminate the virus, and only suppress its proliferation. Thus, even though NAs improve the liver function, the risk of hepatocellular carcinoma (HCC) persists over time. Since a large cohort study which suggested the superiority of tenofovir over entecavir in reducing HCC risk, there is a great deal of controversy in choosing NAs. In this study, we aimed to meta-analyze the published data from Korea to date together with the unpublished data of our institution to derive the robust conclusion. Methods: We searched on-line database and derived 6 publications from Korea. In addition, we investigated 535 treatment- naïve patients with CHB who were first treated with entecavir (n=298) and tenofovir (n=237) between 2008 and 2016 at Korea University Medical Center (Ansan and Guro Hospitals). We used Kaplan-Meier method, Cox regression model, propensity score matching and meta-analysis. Results: From the 6 publications, 9,844 patients were included, 556 developed HCC. From our institutions, HCC was developed in 59 patients during a median follow-up of 21.6 months. After 1:1 propensity score matching, the kind of antiviral agent did not affect the development of HCC (HR, 0.72; 95% CI 0.31-1.71; P=0.46). Combined with the results of six domestic studies, the tenofovir group did not show significant suppression of HCC development compared to the entecavir group (HR, 0.96; 95% CI 0.74-1.25). Conclusions: In a meta-analysis of seven studies of HBV-endemic area including our own institutional data, HCC occurrence was not significantly different between patients with treated with entecavir or tenofovir.
( Tae Hyung Kim ),( Soon Ho Um ),( Yoo Ra Lee ),( Han Ah Lee ),( Sun Young Yim ),( Young Sun Lee ),( Sang Jun Suh ),( Young Kul Jung ),( Yeon Seok Seo ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Jong Eun Y 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Decompensation in patients with liver cirrhosis deteriorates the quality of life and reduces the survival sharply. It is well-known that treatment with nucleos(t)ide analogues can restore liver function, resolve the decompensation and reduce mortality in patients with hepatitis B virus (HBV) related cirrhosis. This study aimed to reveal the efficacy of entecavir and tenofovir, which are preferred as initial treatment for chronic hepatitis B, in patients with HBV-related decompensated cirrhosis Methods: Patients with HBV-related decompensated cirrhosis who received entecavir or tenofovir as the initial antiviral therapy were retrospectively identified. Patients with chronic kidney disease or coexisting malignancy, such as hepatocellular carcinoma, were excluded. The primary outcome was the compensation, defined as reduction of Child-Pugh-Turcotte (CTP) score to five. Results: A total of 251 patients were enrolled. Mean age was 53.6 ± 10.8 years and 147 patients (58.6%) were men. CTP grade C presented in 146 patiens (58.2%). During a median follow-up of 34.3 months, the compensation and death occurred in 153 and 71 patients, respectively. Kaplan-Meier plots showed that type of antiviral agents did not influence significantly on compensation (log-rank test, P=0.088) and survival (P=0.295). In multivariate Cox-regression analysis, the compensation significantly occurred more frequently with lower BMI (odds ratio [OR], 0.955; 95% confidence interval [CI], 0.918- 0.993; P=0.021), higher platelet count (OR, 1.006; 95% CI, 1.004-1.011; P<0.001), log value of serum AFP level (OR, 1.905; 95% CI, 1.486-2.443; P<0.001) and absense of ascites (OR, 1.762; 95% CI, 1.234-2.517; P=0.002). Conclusions: The effects on prognosis of HBV-related decompensated cirrhosis were comparable between entecavir and tenofovir. We identified four predictive factors including BMI, platelet count, serum AFP level and ascites for reversibility of decompensation in patients with HBV-related cirrhosis.
Kim Tae Hyung,Kim Ji Hoon,Yim Hyung Joon,Seo Yeon Seok,Yim Sun Young,Lee Young-Sun,Jung Young Kul,Yeon Jong Eun,Um Soon Ho,Byun Kwan Soo 거트앤리버 소화기연관학회협의회 2024 Gut and Liver Vol.18 No.2
Background/Aims: Besifovir dipivoxil maleate (BSV) and tenofovir alafenamide fumarate (TAF) have been recently approved in Korea as the initial antiviral agents for chronic hepatitis B (CHB). However, the real-world outcome data for these drugs remain limited. Therefore, we conducted a noninferiority analysis using real-world data to compare the clinical outcomes of the two nucleotide analogs in treatment-naïve patients with CHB. Methods: We retrospectively investigated a cohort of patients with CHB who received BSV or TAF as first-line antiviral agents. The endpoints were virological response (VR) and liver-related clinical outcomes. Results: A total of 537 patients, consisting of 202 and 335 patients administered BSV and TAF, respectively, were followed up for 42 months. No significant difference was observed between the VRs of the patients from the two groups. The rates of biochemical response, virologic breakthrough, and incidence rates of hepatocellular carcinoma did not differ between the groups. However, the hepatitis B e antigen seroclearance rate was higher and the renal function declined less in the BSV group. Multivariable analysis indicated older age, alcohol abuse, cirrhosis and ascites, and lower serum HBV DNA level to be independently associated with increased hepatocellular carcinoma risk. The 1:1 propensity score-matched analysis with 400 patients showed VR rates of 85.0% and 88.7% in the BSV and TAF group patients, respectively, at 2 years. The absolute value of the 95% confidence interval for the difference (–0.04 to 0.12) satisfied the a priori limit of a noninferiority of 0.15. Conclusions: BSV is noninferior to TAF in terms of VR, and their clinical outcomes are comparable to CHB.
( Sun Young Yim ),( Tae Hyung Kim ),( Suh Sang Jun ),( Eun Sun Kim ),( Bora Keum ),( Yeon Seok Seo ),( Hyung Joon Yim ),( Yoon Tae Jeen ),( Hoon Jai Chun ),( Hong Sik Lee ),( Soon Ho Um ),( Chang Duck 대한간학회 2017 Gut and Liver Vol.11 No.3
Background/Aims: We aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B (CHB). Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 hepatitis B e antigen [HBeAg]-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous. The histologic activity index (HAI) and fibrosis stage followed Ishak system. Results: In HBeAg-positive patients, older age, increased HAI score, advanced fibrosis, and reduced viral load were observed when HBcAg expression shifted from nucleus to cytoplasm in HBcAg-positive patients, and HBsAg expression from non-submembranous to submembranous in HBcAg-negative patients (all, p<0.05). In HBeAg-negative patients, only intracytoplasmic HBsAg expression patterns had clinical relevance with decreased ALT levels and viremia. In HBeAg-positive patients without favorable predictors of virologic response, negative HBcAg and membranous HBsAg expression predicted greater virologic response (both, p<0.05). The probability of HBeAg seroclearance was higher in patients with increased HAI or lacking HBcAg expression (both, p<0.05). Higher serum HBsAg levels and hepatocyte HBcAg positivity were associated with reduced serum HBsAg during first and post-first year treatment, respectively (both, p<0.05). Conclusions: Hepatocyte HBcAg/HBsAg expression is a good marker for disease status and predicting treatment response. (Gut Liver 2017;11:417-425)
( Sun Young Yim ),( Yoo Ra Lee ),( Han Ah Lee ),( Tae Hyung Kim ),( Hyung Joon Yim ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Soon Ho Um ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Sorafenib is the only standard treatment for advanced hepatocellular carcinoma with (HCC). However, its efficacy is not satisfactory and other treatment options are required. This study investigated the efficacy of chemoembolization and hepatic arterial infusion chemotherapy (HAIC) with or without radiotherapy versus sorafenib alone in patients with portal vein thrombosis (PVT). Methods: This single-center retrospective study involved 105 patients of advanced HCC with portal vein tumor thrombosis (PVT). Enrolled patients had either child-pugh (CP) class A or B liver cirrhosis whom were classified into 3 groups: 1) Sorafenib alone, n=20; 2) Chemoembolization and HAIC, n=26; 3) Chemoembolization and HAIC with radiotherapy, n=59. Sorafenib was initiated with 400mg twice daily and HAIC was based on cisplatin and 5-fluorouracil regimen, performed every 4 weeks. Response of PVT was determined 3 months after completion of treatment and was regarded as responsive when there is at least partial response. Overall survival (OS) was analyzed among the treatment groups and factors associated with mortality were evaluated using multivariate analysis. Results: The median radiation dose, sorafenib treatment duration and chemoembolization sessions were 50 Gy, 40 days, and 4 sessions, respectively. Proportion of patients according to the degree of PVT (main/both vs. first order vs. segmental PV) and bilobar tumor mass involvement did not differ among the three groups of treatment. However, PVT response rate was significantly higher in group 3 (13.5% vs. 6.7% vs. 55%, P=0.014) with lower incidence of solid organ metastasis (60% vs. 23.1% vs. 18.6%, P=0.001) and child pugh class B (70%, 50%, 25.4%%, P=0.001) compared to other groups. In univariate cox analysis, treatment modalities, presence of either lymph node or other organ metastasis, CP class B, decrease in AFP levels were associated with survival. However, multivariate analysis revealed that treatment modalities (group 1 vs. 2, HR, 0.244; 95% CI, 0.06-0.999, P=0.05, group 1 vs. 3, HR, 0.121; 95% CI 0.028-0.51, P=0.004 and group 2 vs. 3, HR 0.495; 95% CI, 0.25-0.98, P=0.044) and decrease in serum AFP level within 2 months of treatment (HR, 1.813; 95% CI, 1.204-2.72; P=0.004) were the only independent factors associated with survival. Median OS was significantly higher in patient treated with radiotherapy (group3, 11.1 months) than group 2 (3.6 months, log rank P<0.001) and group 1 (2 months, P<0.001). Furthermore, median OS survival was still significantly greater in group 2 than group 1, P=0.008. Conclusions: Radiotherapy with chemoembolization and HAIC can be alternative treatment option to sorafenib in patients with advanced HCC and PVT.